Alzheimer’s disease (AD) is the most common neurodegenerative disease leading to dementia. In a study published in the Journal of Nanobiotechnology, researchers have reported a successful novel targeted drug delivery system for AD in a mouse model. Multiple clinical trials using anti-Aβ antibodies to treat AD have been unsuccessful, with the blood-brain barrier (BBB) being the probable cause of preventing the antibodies from entering the brain.
This challenge was overcome with glucosylated polymeric nanomicelles (PMs) that can successfully cross the BBB. The study results indicate that administering anti-AβO antibody fragments via PMs reduces the amounts of toxic Aβ species significantly, leading to the formation of less dense Aβ plaques compared to the untreated mice. The PM-encapsulated antibody fragments could cross the BBB and thereby represent an effective way to slow down AD…
